 |
| Olof
Blix, MD |
Medical
Director, Methadone Clinic at the Bergen Clinics Foundation
(Norway)
|
| Naomi
Braine |
Project
Director, The Baron Edmond de Rothschild Chemical Dependency
Institute (United States)
|
| Veronica
Catan |
Project
Director, The Baron Edmond de Rothschild Chemical Dependency
Institute (United States)
|
| Holly
Catania, JD |
Project
Director, International Center for Advancement of Addiction
Treatment
|
| Barbara
Cooper-Gordon |
Administrative
Director, Stuyvesant Square Chemical Dependency Treatment Services
(United States)
|
| Anne
Coppel, MD |
Director,
Emergence Espace-Tolbiac, Paris (France)
|
| Addie
Corradi |
Administrative
Director, Methadone Maintenance Treatment Program (United States)
|
| Don
C. Des Jarlais, PhD* |
Director,
Research, The Baron Edmond de Rothschild Chemical Dependency
Institute (United States)
|
| Vincent
Dole, MD |
Professor
Emeritus, The Rockefeller University (United States)
|
| Herbert
Elias, MD |
General
Medicine Physician, specializing in the treatment of patients
with opiate addiction (Germany)
|
| Paul
H. Epstein, Esq* |
Partner,
Proskauer Rose LLP, NYC
President, The Edmond de Rothschild Foundation (United States)
|
| Loretta
P. Finnegan, MD |
Medical
Advisor to the Director, Office of Research on Women's Health
(United States)
|
| Mitchell
A. Kaplan, PhD |
Research
Project Manager, Institute for Education and Research in the
Department of Pain Medicine and Palliative Care at Beth Israel
Medical Center (United States)
|
| Stanley
Komaroff, Esq* |
Partner,
Proskauer Rose LLP, NYC
Director, The Edmond de Rothschild Foundation (United States)
|
| William
Lowenstein, MD* |
Director,
Center for Addiction Medicine, Centre Monte Cristo Laennec,
Paris (France)
|
| Courtney
McKnight |
Project
Director, The Baron Edmond de Rothschild Chemical Dependency
Institute (United States)
|
| Judith
Milliken |
Administrative
Coordinator, The Baron Edmond de Rothschild Chemical Dependency
Institute (United States)
|
| Ethan
A. Nadelmann, PhD, JD* |
Executive
Director, The Lindesmith Center-Drug Policy Foundation (United
States)
|
| Robert
G. Newman, MD* |
Director,
The Baron Edmond de Rothschild Chemical Dependency Institute
(United States)
|
| Russell
K. Portenoy, MD* |
Chairman,
Department of Pain Medicine and
Palliative Care, Beth Israel Medical Center (United States)
|
| Marc
Reisinger, MD |
Vice-President, European
Opiate Addiction Treatment Association (EUROPAD)
|
| Beverly
L. Richman, MD |
Chief,
Medical Services, Methadone Maintenance Treatment Program (United
States)
|
| Howard
J. Rosso, RN |
Director,
Patient Care Services, Methadone Maintenance Treatment Program
(United States)
|
| Nadim
Salomon, MD |
Medical
Director, Peter Krueger Center for Immunological Disorders (United
States)
|
| Edwin
A. Salsitz, MD |
Director,
Methadone Medical Maintenance Program (United States)
|
| Peter
Vanderkloot |
Advocate
for Patient Rights (United States)
|
| Alex
Wodak, MD |
Director
of the Alcohol and Drug Service, St. Vincent's Hospital, Darlinghurst
(Australia)
|
| Stanley
Yancovitz, MD |
Chief,
Division of Chemical Dependency & Medical Director of Stuyvesant
Square Chemical Dependency Treatment Services (United States)
|
| Stuart
C. Yudofsky, MD* |
Professor
and Chairman, Department of Psychiatry and Behavioral Sciences
Baylor College of Medicine, Houston, TX (United States)
|
| Catherine
Zadoretzky |
Research
Associate, The Baron Edmond de Rothschild Chemical Dependency
Institute (United States) |
*
Member of the Advisory Committee, The International Center for Advancement
of Addiction Treatment of The Baron Edmond de Rothschild Chemical
Dependency Institute
|
|
